We found that apigenin sensitizes primary lung cancer cells to TRAIL-induced apoptosis by concomitantly reducing the levels of the splice variant c-FLIPS and altering the abundance of DR5 splice variants, resulting in increased DR5 receptor expression, thus contributing to improved TRAIL efficacy. This evidence concerns the gene TNFSF10 and lung cancer.